Completed PHASE2 INTERVENTIONAL NCT00019396

flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer

Phase II Study of Flt3 Ligand Alone or in Combination With Melanoma Peptide Immunization in Patients With Metastatic Melanoma or Renal Cell Cancer

Sponsor: National Cancer Institute (NCI)

Conditions Recurrent Melanoma Recurrent Renal Cell Cancer Stage IV Melanoma Stage IV Renal Cell Cancer

Interventions MART-1 antigen Montanide ISA-51 flt3 ligand gp100 antigen tyrosinase peptide

Updated 6 times since 2017 Last updated: Feb 29, 2024 Started: Feb 28, 1998 Completion: Mar 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Recurrent Melanoma and Recurrent Renal Cell Cancer, this trial is completed. The trial is conducted by National Cancer Institute (NCI) and has accumulated 6 data snapshots since 1998. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2024 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Apr 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Feb 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bethesda, United States